CaHA Injectable for Facial Use Gains Regulatory Approval in China
The approval makes it the first calcium hydroxylapatite microsphere injectable product approved in China for facial soft tissue augmentation, according to the company.
The approval makes it the first calcium hydroxylapatite microsphere injectable product approved in China for facial soft tissue augmentation, according to the company.
The certification confirms Renuva’s compliance with the EU’s updated medical device standards for treating acne scars and striae.